Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Triamcinolone Acetonide, Bupivacaine Hydrochloride, Dexmedetomidine.
- Who it may be relevant to
- Registry conditions: Chronic Knee Pain. Basic parameters: 40 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Intra-articular Dexmedetomidine for Treatment of Chronic Knee Pain: A Prospective Case-Control Clinical Trial
Overview
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
Interventions
- Drug Triamcinolone Acetonide
1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain - Drug Bupivacaine Hydrochloride
20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain - Drug Dexmedetomidine
Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Primary outcome measures
- Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection. [Time frame: 7 months]
Eligibility criteria
Inclusion criteria
- Patients were not assigned for surgical intervention;
- Patients were free of exclusion criteria
Exclusion criteria
- Patients were assigned for surgical intervention;
- Patients who had uncontrolled hypertension and/or diabetes mellitus;
- Patients who had uncompensated cardiac, renal, or hepatic diseases;
- Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
- Patients who refused to sign the informed consent were excluded from the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT06641206 · 36264PR843/9/24